Basic Information
Cellmid is an accelerator in the Australian life sciences sector with lead programs in multiple disease indications. The company develops and commercializes innovative new therapies and diagnostic tests for fibrotic diseases, cancer, cardiac ischemic conditions, and hair loss through its wholly-owned subsidiaries. Cellmid holds the world's largest and most comprehensive intellectual property portfolio related to the novel targets midkine (MK) and FGF5. Through its Advangen business, Cellmid markets its FGF5 inhibitor hair growth products in Australia, Japan, and the United States, while expanding distribution into other regions.